MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

77.23 2.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

73.41

Максимум

77.25

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+80.31% upside

Дивиденти
By Dow Jones
Следващи печалби	6.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-650M 5.8B
Предишно отваряне	74.83
Предишно затваряне	77.23

Настроения в новините

By Acuity

43%

57%

151 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.03.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30.03.2026 г., 22:36 ч. UTC

Значими събития в новините

Australian Government Rules Out Boots on the Ground in the Middle East

30.03.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30.03.2026 г., 21:00 ч. UTC

Печалби

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30.03.2026 г., 20:15 ч. UTC

Значими събития в новините

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30.03.2026 г., 23:40 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.03.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30.03.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30.03.2026 г., 22:49 ч. UTC

Пазарно говорене

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30.03.2026 г., 22:44 ч. UTC

Пазарно говорене

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30.03.2026 г., 22:43 ч. UTC

Пазарно говорене

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30.03.2026 г., 22:42 ч. UTC

Пазарно говорене

South32 Should Go for Growth, Says New Bull -- Market Talk

30.03.2026 г., 22:18 ч. UTC

Пазарно говорене

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30.03.2026 г., 22:05 ч. UTC

Пазарно говорене

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30.03.2026 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Financial Agrees to Buy Bell Partners for $350M

30.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30.03.2026 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30.03.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30.03.2026 г., 21:03 ч. UTC

Придобивния, сливания и поглъщания

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.03.2026 г., 20:09 ч. UTC

Печалби

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30.03.2026 г., 20:00 ч. UTC

Значими събития в новините

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

80.31% нагоре

12-месечна прогноза

Среден 136.71 USD 80.31%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

151 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.